Abstract | BACKGROUND: OBJECTIVE: FINDINGS: CONCLUSION:
Entecavir represents a new first- or second-line treatment option for patients chronically infected with HBV. Long-term efficacy and safety studies as well as studies of entecavir in combination with interferon products or other nucleoside/ nucleotide analogs are eagerly awaited.
|
Authors | Anastasia Rivkin |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 21
Issue 11
Pg. 1845-56
(Nov 2005)
ISSN: 0300-7995 [Print] England |
PMID | 16307706
(Publication Type: Journal Article, Review)
|
Chemical References |
- Reverse Transcriptase Inhibitors
- Lamivudine
- entecavir
- Guanine
|
Topics |
- Animals
- Clinical Trials as Topic
- Guanine
(analogs & derivatives, pharmacokinetics, therapeutic use)
- Hepatitis B virus
(metabolism)
- Hepatitis B, Chronic
(drug therapy, physiopathology)
- Humans
- Lamivudine
(therapeutic use)
- Practice Guidelines as Topic
- Randomized Controlled Trials as Topic
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Treatment Outcome
|